Fulminant Influenza A myocarditis in a patient presenting with cardiogenic shock and biventricular thrombi: a case report.
Mylène CottetHari VivekananthamJosé David ArrojaDiego ArroyoPublished in: European heart journal. Case reports (2022)
Fulminant myocarditis due to Influenza A is rare and, to the best of our knowledge, has not been associated with intracardiac thrombi formation. Echocardiography is the essential first-line imaging modality. Cardiac magnetic resonance plays a major role in the diagnosis of myocarditis and may preclude the need for an endomyocardial biopsy in selected cases. Coronary angiography may be required to rule out ischaemic aetiology. First-line therapy in fulminant disease is pharmacological and, if required, mechanical haemodynamic support. Standard HF therapy complete the therapeutic options and should be introduced as soon as possible. Complications such as intracardiac thrombi formation, require targeted treatment. Specific drug therapies targeting Influenza A have no proven benefit in myocarditis.
Keyphrases
- magnetic resonance
- left ventricular
- case report
- healthcare
- cancer therapy
- liver failure
- high resolution
- left atrial appendage
- computed tomography
- risk factors
- pulmonary hypertension
- stem cells
- magnetic resonance imaging
- heart failure
- cardiac resynchronization therapy
- drug delivery
- cell therapy
- contrast enhanced
- fluorescence imaging
- combination therapy
- ultrasound guided